Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Stokes

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Postgraduate Medicine|December 6, 2017
When bigger isn't betterJohn D Stokes, Sarah L Gall
Annals of Internal Medicine|September 3, 2002
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack TrialBarry R Davis, Jeffrey A Cutler, Curt D Furberg, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 30, 2013
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 5, 2013
Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Postgraduate Medicine|December 6, 2017
When bigger isn't betterJohn D Stokes, Sarah L Gall
Annals of Internal Medicine|September 3, 2002
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack TrialBarry R Davis, Jeffrey A Cutler, Curt D Furberg, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 30, 2013
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 5, 2013
Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?Karen L Margolis, Barry R Davis, Charles Baimbridge, et al.
Pageof 1